BioDlink Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 594

Employees

  • Stock Symbol
  • 01875

Stock Symbol

  • Share Price
  • $0.43
  • (As of Friday Closing)

BioDlink General Information

Description

BioDlink International Co Ltd is an investment holding company. The Company is mainly engaged in research and development (R&D), manufacturing, and marketing of anti-tumor drugs, contract development and manufacturing organization (CDMO), contract manufacturing organization (CMO) business and license-out of self-developed biological drugs. The company has presence in Mainland China, and Others. The company's services includes ADC R&D Service Platform, Chemical based conjugation process development, Developability assessment for drug product, Drug substance analysis, Antibody Manufacturing, Drug product analysis, etc.

Contact Information

Formerly Known As
TOT Biopharm
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Dongyao Pharmaceutical Co., Ltd., Number 120 Changyang Street, Suzhou Industrial Park
  • Suzhou, Jiangsu 215024
  • China
+86 0512
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
HKG
Vertical(s)
Corporate Office
  • Dongyao Pharmaceutical Co., Ltd., Number 120 Changyang Street, Suzhou Industrial Park
  • Suzhou, Jiangsu 215024
  • China
+86 0512

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioDlink Stock Performance

As of 20-Nov-2026, BioDlink’s stock price is $0.43. Its current market cap is $312M with 725M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.43 $0.42 $0.22 - $0.75 $312M 725M 454K -$0.03

BioDlink Financials Summary

As of 30-Jun-2026, BioDlink has a trailing 12-month revenue of $72.1M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 311,307 234,847 172,123 168,676
Revenue 72,101 103,965 153,067 110,338
EBITDA (21,920) (1,599) 14,866 1,056
Net Income (23,287) (13,957) 4,844 (5,337)
Total Assets 172,741 179,983 206,678 201,182
Total Debt 51,661 54,820 54,173 48,762
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BioDlink Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BioDlink‘s full profile, request access.

Request a free trial

BioDlink Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
BioDlink International Co Ltd is an investment holding company. The Company is mainly engaged in research and developmen
Drug Discovery
Suzhou, China
594 As of 2026

Bengaluru, India
 

Hyderabad, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioDlink Competitors (23)

One of BioDlink’s 23 competitors is Biocon, a Formerly PE-Backed company based in Bengaluru, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biocon Formerly PE-Backed Bengaluru, India
Aurobindo Pharma Corporation Hyderabad, India
Roche Corporation Basel, Switzerland
Torrent Pharmaceuticals Corporation Ahmedabad, India
Novartis Corporation Basel, Switzerland
You’re viewing 5 of 23 competitors. Get the full list »

BioDlink Patents

BioDlink Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025067393-A1 Disaccharide-acylhydrazone or disaccharide-hydrazide linker, glyco-engineered antibody and sugar-chain site-directed antibody-drug conjugate based on same, and use thereof Inactive 28-Sep-2023
WO-2025067404-A1 Endoglycosidase s2 mutant, preparation method therefor and use thereof in antibody glycosylation modification Inactive 28-Sep-2023
WO-2024120526-A1 Anti-ilt4 antibody as well as preparation method therefor and use thereof Inactive 09-Dec-2022
WO-2020073883-A1 Syringe and auxiliary dosing device for syringe Inactive 08-Oct-2018 A61M5/315

BioDlink Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioDlink Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BioDlink‘s full profile, request access.

Request a free trial

BioDlink ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view BioDlink’s complete esg history, request access »

BioDlink Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Yaozhan Pharmaceutical Suzhou, China 2021

BioDlink FAQs

  • When was BioDlink founded?

    BioDlink was founded in 2010.

  • Where is BioDlink headquartered?

    BioDlink is headquartered in Suzhou, China.

  • What is the size of BioDlink?

    BioDlink has 594 total employees.

  • What industry is BioDlink in?

    BioDlink’s primary industry is Drug Discovery.

  • Is BioDlink a private or public company?

    BioDlink is a Public company.

  • What is BioDlink’s stock symbol?

    The ticker symbol for BioDlink is 01875.

  • What is the current stock price of BioDlink?

    As of 20-Nov-2026 the stock price of BioDlink is $0.43.

  • What is the current market cap of BioDlink?

    The current market capitalization of BioDlink is $312M.

  • What is BioDlink’s current revenue?

    The trailing twelve month revenue for BioDlink is $72.1M.

  • Who are BioDlink’s competitors?

    Biocon, Aurobindo Pharma, Roche, Torrent Pharmaceuticals, and Novartis are some of the 23 competitors of BioDlink.

  • What is BioDlink’s annual earnings per share (EPS)?

    BioDlink’s EPS for 12 months was -$0.03.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process